Loading…
Loading…
LFMD does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LFMD and 80,000+ other tickers.
See exactly how LFMD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LFMD and 80,000+ other tickers.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical…
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47. 3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3. 5 million, improving approximately 21% sequentially. Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.